Abstract:
:Bortezomib is an inhibitor of the ubiquitin-proteasome proteolytic pathway responsible for intracellular protein turnover. Cellular proteins controlled by this pathway represent a diverse group of potential therapeutic targets, particularly in cancer cells, which exploit this proteasomal pathway to promote their growth and diminish apoptosis. Along with inhibiting the proteasome and thus sensitizing tumor cells to apoptosis, bortezomib may also have multiple effects on the host immune responses. This review summarizes the effects that bortezomib may play on immune cell subsets in various disease states in modifying lymphocyte receptors, ligands, the expression of various cytokines and chemokines and their downstream signaling. We also propose steps that can be taken to refine combinatorial strategies that include bortezomib to improve current immunotherapeutic approaches.
journal_name
Immunotherapyjournal_title
Immunotherapyauthors
Pellom ST Jr,Dudimah DF,Thounaojam MC,Sayers TJ,Shanker Adoi
10.2217/imt.15.66subject
Has Abstractpub_date
2015-01-01 00:00:00pages
1011-22issue
9eissn
1750-743Xissn
1750-7448journal_volume
7pub_type
杂志文章,评审相关文献
Immunotherapy文献大全abstract::Aim: To evaluate treatment results in advanced/metastatic melanoma patients treated with anti-PD-1 immunotherapy in routine practice in oncology centers in Poland. Methods: Multicenter retrospective analysis included 499 patients with unresectable/metastatic (stage IIIC-IV) melanoma treated with anti-PD-1 in first-lin...
journal_title:Immunotherapy
pub_type: 杂志文章
doi:10.2217/imt-2020-0217
更新日期:2021-03-01 00:00:00
abstract::HER2/neu is expressed in the majority of in situ breast cancers, but maintained in 20-30% of invasive breast cancer (IBC). During breast tumorigenesis, there is a progressive loss of anti-HER2 CD4(pos) Th1 (anti-HER2Th1) from benign to ductal carcinoma in situ, with almost complete loss in IBC. This anti-HER2Th1 respo...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt-2016-0052
更新日期:2016-10-01 00:00:00
abstract::FOCIS goes South: Advances in Translational and Clinical Immunology was the first Federation of Clinical Immunology Societies (FOCIS) ( www.focisnet.org ) meeting held in Latin America (May 15-17, 2017, Santiago de Chile, Chile). The meeting was organized as a 3-day workshop and was fostered by the Millennium Institut...
journal_title:Immunotherapy
pub_type:
doi:10.2217/imt-2017-0079
更新日期:2017-09-01 00:00:00
abstract::Evaluation of: Bostrom J, Shang-Fan Y, Kan D et al.: Variants of the antibody Herceptin that interact with HER2 and VEGF at the antigen binding site. Science 323, 1610-1614 (2009). The longstanding held notion that one antibody equals one antigen and, hence, one function has been challenged in recent years. Improved t...
journal_title:Immunotherapy
pub_type: 评论,杂志文章
doi:10.2217/imt.09.39
更新日期:2009-09-01 00:00:00
abstract::Following cancer treatment, patients often report behavioral and cognitive changes. Novel cancer immunotherapeutics have the potential to produce sustained cancer survivorship, meaning patients will live longer with the side effects of treatment. Given the role of inflammatory pathways in mediating behavioral and cogn...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt-2017-0056
更新日期:2017-09-01 00:00:00
abstract::Background: Severe pneumonia and acute respiratory distress syndrome (ARDS) due to COVID-19 is a challenge for nowadays medical practice. Although there is no clarity in the principal mechanism of lung damage and ARDS development, it has been suggested that one of the main reasons of this pathology is the hyperactivat...
journal_title:Immunotherapy
pub_type: 杂志文章
doi:10.2217/imt-2020-0154
更新日期:2020-10-01 00:00:00
abstract::Programmed cell death-1 protein (PD-1) is an immune checkpoint that has gained popularity in the treatment of several advanced cancers. Inhibiting this checkpoint is known to enhance immune response, but is also known to diminish immune tolerance and to increase autoimmune toxicity. We discuss a case of rapid onset fu...
journal_title:Immunotherapy
pub_type: 杂志文章
doi:10.2217/imt-2017-0020
更新日期:2017-06-01 00:00:00
abstract::In COVID-19, the inflammatory cytokine-release syndrome is associated with the progression of the disease. Itolizumab is a monoclonal antibody that recognizes human CD6 expressed in activated T cells. The antibody has shown to be safe and efficacious in the treatment of moderate to severe psoriasis. Its effect is asso...
journal_title:Immunotherapy
pub_type: 杂志文章
doi:10.2217/imt-2020-0235
更新日期:2021-03-01 00:00:00
abstract::Background: Progress in immunotherapy (IT) has shifted treatment paradigms for multiple malignancies. In March 2019, the combination of nab-paclitaxel and atezolizumab was approved by the US FDA for patients with PD-L1 positive metastatic triple-negative breast cancer based on positive results of the Impassion130 tria...
journal_title:Immunotherapy
pub_type: 杂志文章
doi:10.2217/imt-2020-0202
更新日期:2020-12-01 00:00:00
abstract::Acute pyelonephritis is an infection of the renal parenchyma and renal pelvis. When it is caused by a typical pathogen in an immunocompetent female patient with normal urinary tract, it is considered uncomplicated. In all other cases, sepsis is the most worrisome complication. In the event of sepsis, patients should b...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt.15.98
更新日期:2016-01-01 00:00:00
abstract::Over the last two decades, anti-CD20 monoclonal antibody (mAb) therapy has improved patient outcome in B-cell malignancies, and confirmed CD20 as an important target in chronic lymphocytic leukemia (CLL). Until recently, the gold standard was based on the utilization of rituximab combined with chemotherapy (fludarabin...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt-2015-0015
更新日期:2016-05-01 00:00:00
abstract::Sarcoidois is an inflammatory disease of unknown origin characterized by the abnormal accumulation of noncaseating granulomas at sites of disease activity in multiple organs throughout the body with a predilection for the lungs. Because the exact trigger that leads to disease activity is still under investigation, cur...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt.14.103
更新日期:2015-01-01 00:00:00
abstract::Aim: To analyze the efficacy of checkpoint inhibitors in soft tissue sarcoma. Materials & methods: We retrospectively reviewed patients with advanced soft tissue sarcoma treated with ipilimumab and nivolumab. All patients who received at least one cycle were included. Results: One patient had a complete response and f...
journal_title:Immunotherapy
pub_type: 杂志文章
doi:10.2217/imt-2020-0155
更新日期:2020-12-01 00:00:00
abstract::Developing effective vaccines against Neisseria meningitidis serogroup B has been challenging for several reasons, including the fact that the capsular polysaccharide of N. meningitidis serogroup B is a poor antigen. Therefore, studies have focused on developing vaccines that target capsular protein meningococcal anti...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt.14.11
更新日期:2014-01-01 00:00:00
abstract::Activation of a patient's immune system offers an attractive approach to prevent and treat hepatocellular carcinoma (HCC). However, the antitumor efficacy of current HCC vaccines was weak owing to insufficient immune activation of targeting self/tumor antigens. We recently found that epitope-optimized α-fetoprotein ef...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt.14.46
更新日期:2014-01-01 00:00:00
abstract::Immunotherapy strategies for cancer are focused on inducing effective and specific cytotoxic responses mediated by CD8 T cells. On the other hand, immunosuppressive mechanisms induced by the tumor, such as the generation of tumor-specific CD4(+)CD25(+)FoxP3(+) Tregs, conspire against the efficacy of immunotherapies. I...
journal_title:Immunotherapy
pub_type: 杂志文章
doi:10.2217/imt.12.39
更新日期:2012-05-01 00:00:00
abstract::Background: CD19-targeted chimeric antigen receptor (CAR) T-cell therapy has emerged as a powerful immunotherapy in relapsed or refractory B-cell acute lymphoblastic leukemia. The changes in extramedullary (EM) disease in pediatric relapsed or refractory B-cell acute lymphoblastic leukemia after CAR T-cell therapy hav...
journal_title:Immunotherapy
pub_type: 杂志文章
doi:10.2217/imt-2020-0188
更新日期:2021-01-01 00:00:00
abstract::Epstein-Barr virus-associated lymphoproliferative diseases (EBV-LPD) after hematopoietic stem cell transplantation or solid-organ transplantation remain a serious and potentially life-threatening complication. In the last decade, outcomes for EBV-LPD have significantly improved. Key to this success was the development...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt.10.43
更新日期:2010-09-01 00:00:00
abstract::Myeloid-derived suppressor cells (MDSCs) are immature myeloid cells that infiltrate human and experimental tumors and strongly inhibit anticancer immune response directly or by inducing regulatory T-lymphocyte activity. Consequently, MDSCs are important actors of cancer-induced immune tolerance and a major obstacle to...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt.11.154
更新日期:2012-01-01 00:00:00
abstract::Pediatric eosinophilic esophagitis is an inflammatory condition associated with marked eosinophil accumulation in the mucosal tissues of the esophagus. Eosinophils are major proinflammatory cells thought to make a major contribution to allergic diseases that affect the upper and lower airways, skin and GI tract. IL-5 ...
journal_title:Immunotherapy
pub_type: 杂志文章
doi:10.2217/imt.10.41
更新日期:2010-07-01 00:00:00
abstract::In recent years, nanoparticulate-mediated drug delivery research has examined a full spectrum of nanoparticles that can be used in diagnostic and therapeutic cancer applications. A key aspect of this technology is in the potential to specifically target the nanoparticles to diseased cells using a range of molecules, i...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt.11.5
更新日期:2011-03-01 00:00:00
abstract::Melanoma antigen family A, 3 (MAGE-A3) is a cancer-testis antigen whose expression has been demonstrated in a wide array of malignancies including melanoma, brain, breast, lung and ovarian cancer. In addition, its ability to elicit spontaneous humoral and cellular immune responses has been shown in cancer patients. As...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt.15.29
更新日期:2015-01-01 00:00:00
abstract::In spite of the considerable successes that have been achieved in the treatment of chronic myeloid leukemia (CML), cure for the disease can only be obtained by the present means in a rather small minority of patients. During the past decade, considerable progress has been made in the understanding of the immunology of...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt.10.2
更新日期:2010-03-01 00:00:00
abstract::Lactobacilli are a group of normal microbiota whose immunomodulatory effects have been known for a long time. Recently, they have gained more attention for their direct and indirect effects on cancer cells. Several cell line experiments, animal model studies as well as clinical trials have indicated their inhibitory e...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt.15.92
更新日期:2015-01-01 00:00:00
abstract::Mycobacterium tuberculosis was one of the first human pathogens to be identified as the cause of a specific disease--TB. TB was also one of the first specific diseases for which immunotherapy was attempted. In more than a century since, multiple different immunotherapies have been attempted, alongside vaccination and ...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt.12.52
更新日期:2012-06-01 00:00:00
abstract:AIM:Few studies have compared cluster immunotherapy and conventional administration regimens. The aim of this study was to establish the safety profile of these different regimens in patients with allergic respiratory diseases who received index-of-reactivity (IR)-standardized allergen extracts by the subcutaneous rout...
journal_title:Immunotherapy
pub_type: 杂志文章,多中心研究
doi:10.2217/imt.13.133
更新日期:2013-12-01 00:00:00
abstract::The rapid emergence of multidrug-resistant pathogens, especially Gram-negative bacteria and mycobacteria, represents one of the major medical challenges of the 21st century. The gradual loss of effective classical antibiotics for many bacterial pathogens, combined with an increasing population density and mobility, ur...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt.13.17
更新日期:2013-04-01 00:00:00
abstract::Renal toxicity from immune checkpoint inhibitors (ICIs) is an increasingly recognized cause of acute kidney injury among patients with cancer. ICI-associated acute kidney injuries typically present as acute interstitial nephritis and the timing of onset is highly variable. Herein, we present a case of a patient with r...
journal_title:Immunotherapy
pub_type: 杂志文章
doi:10.2217/imt-2020-0223
更新日期:2021-03-01 00:00:00
abstract::John L Stanford speaks to Hannah Wilson, Assistant Commissioning Editor John L Stanford is Chief Scientific Officer at BioEos Ltd (Kent, UK). Dr Stanford began his career as a senior lecturer and then reader in microbiology at Middlesex Hospital Medical School (London, UK), then University College London Medical Schoo...
journal_title:Immunotherapy
pub_type: 面试,新闻
doi:10.2217/imt.13.27
更新日期:2013-05-01 00:00:00
abstract::Histone deacetylase inhibitors possess a broad array of antitumor activities; however, their net impact on the evolving antitumor immune response is highly dependent on the inhibitors used and the histone deacetylases they target. Herein, we sequentially focus on each stage of the antitumor immune response - from dend...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt-2017-0134
更新日期:2017-12-01 00:00:00